Pharmaceutical industry, innovation and challenges for public health: Case studies from Malaysia and Pakistan

Journal of Pharmaceutical Health Services Research

Volumn 2, Issue 4, 2011, Pages 193-204

  Babar, Zaheer Ud Din ^a   Ibrahim, Mohamed Izham Mohamed ^b   Hassali, Mohamed Azmi Ahmad ^c  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

^b QASSIM UNIVERSITY   (Saudi Arabia)

^c SCHOOL OF PHYSICS   (Malaysia)

Author keywords

Innovation; Malaysia; Pakistan; Pharmaceutical industry; Public health

Indexed keywords

CASE STUDY; CONSUMER; CONTROLLED STUDY; DEVELOPING COUNTRY; DRUG COST; DRUG INDUSTRY; DRUG MANUFACTURE; DRUG MARKETING; DRUG RESEARCH; DRUG UTILIZATION; ECONOMIC DEVELOPMENT; GOVERNMENT; HEALTH CARE POLICY; MALAYSIA; PAKISTAN; PHARMACEUTICAL CARE; PRESCRIPTION; PRIORITY JOURNAL; PUBLIC HEALTH; PUBLIC-PRIVATE PARTNERSHIP; REVIEW;

EID: 84859812546     PISSN: 17598885     EISSN: 17598893     Source Type: Journal    
DOI: 10.1111/j.1759-8893.2011.00058.x     Document Type: Review

References (65)

1. Swain NM etal. Indian pharmaceutical industry an analysis. In: Krishnaphani K, ed. Pharma Sector: Trends and Cases Volume 1. Dehradun: ICFAIA University Press, 2003.
2. Malhotra P, Lofgren H. India's pharmaceutical industry: hype or high tech take-off? Aust Health Rev 2004; 28: 182-193.
3. Kaplan W, Laing R. Local Production of Pharmaceuticals: Industrial Policy and Access to Medicines. HNP Discussion Paper. Washington, DC: The International Bank for Reconstruction and Development/The World Bank, 2005. (accessed 28 June 2011).
4. Lashman KH. Pharmaceuticals in the Third World: An Overview. PHN Technical Note 86-31. Washington, DC: The World Bank, 1986.
5. Anon. Third Industrial Master Plan, 2006-2020. Kuala Lumpur: Government of Malaysia, Ministry of International Trade and Industry.
6. The Economist Intelligence Unit. Industry Forecast, Malaysia. 2005. (accessed 28 June 2011).
7. Babar ZU etal. Evaluating drug prices, availability, affordability, and price components: implications for access to drugs in Malaysia. PLoS Med 2007; 4: e82.
8. Goh A etal. Expenditure on Medicines in Malaysia: Estimates from Malaysian Statistics on Medicines 2005. Poster at the 7th MOH-AAM Scientific Meeting 2007, Las Vegas, Nevada, USA. (accessed 28 June 2011).
9. Anon. Product Registration and Post Market surveillance in Malaysia - An Overview. Consumer Medicines Surveillance Seminar. Putrajaya: Ministry of Health, Malaysia, National Pharmaceutical Control Bureau, 9 January 2007.
10. Lek CS. More than a politician. Medical Grapevine 2005; Nov/Dec: 7-8.
11. Anon. The Star. 24 April 1993. Malaysia.
12. Huri Z. The Generic Pharmaceutical Industry in Malaysia. Kuala Lumpur: Department of Pharmacy, University of Malaya, 2001 (B.Pharm thesis).
13. Azmi IM, Alavi R. TRIPS, patents, technology transfer, foreign direct investment and the pharmaceutical industry in Malaysia. J World Intellect Prop 2001; 4: 947-976.
14. Cyranoski D. Malaysian biotechnology: the valley of ghosts. Nature 2005; 436: 620-621.
15. Ministry of Health. National Medicines Policy of Malaysia. Putrajaya: Ministry of Health, Malaysia, 2006.
16. Moynihan R, Henry D. The fight against disease mongering: generating knowledge for action. PLoS Med 2006; 3: e191.
17. Anon. Erectile dysfunction: don't suffer in the silence. Men's Health, Advertising Series - 2. [online] 1 October 2004. (accessed 28 June 2011).
18. Anon. Vit C at RM100 per jab: It's the trend for health buffs but be warned. New Straits Times, Malaysia, 17 August 2005.
19. Anon. Doctors in cahoots with drug companies. New Straits Times, Malaysia, 8 May 2007.
20. Gelders S etal. Price, Availability and Affordability: An International Comparison of Chronic Disease Medicines. Cairo: World Health Organization and Health Action International, 2006. (accessed 28 June 2011).
21. Health Action International. Medicine prices survey profile and reports [online]. (accessed 28 June 2011).
22. Babar ZUD etal. Medicine utilization and pricing in Malaysia: The findings of a household survey. J Generic Med 2005; 3: 47-61.
23. Thomas M. Consumers' perceptions of generic medicines and their experiences in community pharmacies in Malaysia. Adelaide: University of South Australia, School of Pharmacy and Medical Sciences, 2007 (Honour thesis).
24. Babar ZU, Awaisu A. Evaluating community pharmacists, perception and practices on generic medicines: a pilot study from peninsular. Malaysia J Generic Med 2008; 5: 315-330.
25. Trap B etal. Prescribing habits of dispensing and non-dispensing doctors in Zimbabwe. Health Policy and Plan 2002; 17: 288-295.
26. Almarsdo' ttir BA, Traulsen MJ. Rational use of medicines - an important issue in pharmaceutical policy. Pharm World Sci 2005; 27: 76-80.
27. Anon. Malaysian Poisons Regulations 1952. Putrajaya: Ministry of Health, Malaysia: Regulation 12 (1), subregulation (ba) and (c). Pharmaceutical Services Division. (accessed 19 February 2007).
28. Babar ZU etal. Self-medication in Malaysia: a case of midazolam poisoning in a tertiary care hospital. Int J Pharm Pract 2006; 14: 159.
29. IMS. Country Profiles: IMS Pakistan [website]. (accessed 28 June 2011).
30. Anon. Prices of drugs in Pakistan are freezed at the level of prices during December 2001. (accessed 28 June 2011).
31. Drug Control Organization, Ministry of Health, Government of Pakistan [online]. (accessed 6 November 2006).
32. World Health Organization. The World Medicines Situation. 2004. WHO/EDM/PAR/2004.5.
33. Export Promotion Bureau, Government of Pakistan [online]. Exports from Pakistan (Pharmaceuticals). (accessed 28 June 2011).
34. Ministry of Commerce. The Trade Policy Speech 2004-2005. Islamabad: Government of Pakistan, Ministry of Commerce, 2004.
35. Ministry of Commerce. The Trade Policy Speech 2005-2006. Islamabad: Government of Pakistan, Ministry of Commerce, 2005.
36. Goliath. Pakistan to promote its pharma products to Cambodia. [Brief online article] (accessed 28 June 2011).
37. Aziz S. Pak Pharmaceutical industry flourishing: PM. Pak Tribune. 25 January 2006.
38. Parab K. Pakistan Pharma - is it on the right path? (accessed 20 July 2011).
39. Hafeez A etal. Prescription and dispensing practices in public sector health facilities in Pakistan: survey report. J Pak Med Assoc 2004; 54: 187-191.
40. Butt ZA etal. Quality of pharmacies in Pakistan: a cross-sectional survey. Int J Qual Health Care 2005; 17: 307-313.
41. Rabbani F etal. Behind the counter: pharmacies and dispensing patterns of pharmacy attendants in Karachi. J Pak Med Assoc 2001; 51: 149.
42. Iqbal M etal. Ofloxacin: laboratory evaluation of the antibacterial activity of 34 brands representing 31 manufacturers available in Pakistan. Pak J Med Sci 2004; 20: 349-356.
43. Jenkes C etal. Data and facts: German drugs in the Third World. Bielefeld: BUKO Pharma-Kampagne, 2004.
44. Rohra DK etal. Critical evaluation of the claims made by pharmaceutical companies in drug promotional material in Pakistan. J Pharm Pharmaceut Sci 2006; 9: 50-59.
45. Jawaid SA, Jafary MH. Relationship between the medical profession and the pharma industry: need for greater scrutiny, transparency and accountability. Pak J Med Sci 2004; 20: 283-291.
46. Mahmood K. Runaway drug prices in Pakistan. Lancet 1993; 342: 809.
47. Kiani A, Qadeer A. Prices, availability and affordability of medicines in Pakistan. [online report] August 2006. Islamabad: The Network for Consumer Protection. (accessed 28 June 2011).
48. Ali I. Drug testing lab imperative to check quality standards. The News International, 29 October 2007 [online]. (accessed 22 January 2008).
49. Mirza Z. Islamabad non-emergence of Pakistan's national drug policy. Lancet 1996; 348: 119.
50. Ministry of Health. National Drug Policy. Drug Control Organization. Islamabad: Government of Pakistan, Ministry of Health, 2003. (accessed 6 March 2011).
51. Tahirkheli MA. Critical analysis of Pakistan NMP. The Watch on Medicines [online]. Islamabad: The Network for Consumer Protection 15 (05) Sep-Oct, 2006.
52. Yasir M. Import duty cut to boost pharmaceutical exports. Daily Times, 25 September 2007.
53. Anon. Punjab to establish drug testing. Express Tribune, 19 April 2011. (accessed 28 June 2011).
54. Vandergrift M, Kanavos P. Health policy versus industrial policy in the pharmaceutical sector: the case of Canada. Health Policy 1997; 41: 241-260.
55. Khan MM, Van den Heuvel W. The impact of political context upon the health policy process in Pakistan. Public Health 2007; 121: 278-286.
56. Anon. Editorial. What price competitiveness in the drug industry? Lancet 2003; 362: 257.
57. Mooraj Z. Pharmaceutical industry [letter, online]. Dawn, 24 June 2005. (accessed 1 November 2006).
58. Export Promotion Bureau. Regional country variation analysis. Karachi: Government of Pakistan, Export Promotion Bureau, 2007.
59. Department of Health. Pharmaceutical Price Regulation Scheme: Seventh Report to Parliament. London: Department of Health, 2003.
60. Ministry of Health. Price Review Committee. Islamabad: Government of Pakistan, Ministry of Health, 2003. (accessed 6 November 2005).
61. Ministry of Health. Draft Drug Regulatory Authority Act, 2006. Government of Pakistan: Ministry of Health, 2006. (accessed 20 June 2011).
62. Anon. Critique by The Network for Consumer Protection on the framework proposed by Ministry of Health, for setting up 'Drug Regulatory Authority'. Islamabad:The Network for Consumer Protection, 2007.
63. Balasubramaniam K. Policies and strategies on drug pricing, regulations & international experience. Penang, Malaysia: International Organization of Consumers Union, Regional Office for Asia and the Pacific, 1988.
64. Almarsdo'ttir BA, Traulsen MJ. Studying and evaluating pharmaceutical policy - becoming a part of the policy and consultative process. Pharm World Sci 2006; 28: 6-12.
65. Noerreslet M etal. The medicine user - lost in translation? Analysis of the official political debate prior to the deregulation of the Danish medicine distribution system. Soc Sci Med 2005; 61: 1733-1740.